INSULIFE AS

Facts

Source: Firmafakta, with business data from public registers.

organisasjonsnummer:

925128554

navn:

INSULIFE AS

organisasjonsform:

kode:

AS

beskrivelse:

Aksjeselskap

naeringskode1:

kode:

21.200

beskrivelse:

Produksjon av farmasøytiske preparater

antallAnsatte:

not reported by source

hjemmeside:

www.insulife.com

epostadresse:

info@insulife.com

telefon:

not reported by source

forretningsadresse:

adresse:

Gaustadalléen 21

poststed:

OSLO

postnummer:

0349

kommune:

OSLO

stiftelsesdato:

2020-03-31

registreringsdatoenhetsregisteret:

2020-06-05

aktivitet:

Utvikle, eie, produsere, markedsføre og drive salg av spray baserte, legemidler samt det som står i forbindelse med dette. Selskapet skal, også kunne delta i andre virksomheter med økonomiske formål.

vedtektsfestetFormaal:

Utvikle, eie, produsere, markedsføre og drive salg av spray baserte, legemidler samt det som står i forbindelse med dette. Selskapet skal, også kunne delta i andre virksomheter med økonomiske formål.

View the address in Geonorge

Board and other roles

Source: Firmafakta. Also see the separate Brønnøysund lookup under related lookups.

Daglig leder

• Daglig leder: Åge Nærdal

Regnskapsfører

• Regnskapsfører: VIEW GROUP AS

Revisor

• Revisor: BDO AS

Styre

• Styremedlem: Per Dybwad
• Styremedlem: Pål Eriksen
• Styremedlem: Anne Waaler
• Styremedlem: Bjørg Eikeland
• Styremedlem: David Weild Iv
• Styremedlem: Gregory David Cash
• Styrets leder: Petter Bjornstad

Owners

Source: Firmafakta shareholder dataset.

Showing top 50 of 755 shareholders by holding size. Raise 'limit' (max 1000) for more.

1. WESSEL CAPITAL LLC – 24.51 % (16991484 shares, share class: NO0012753625)
2. TRANSDERMAL DELIVERY SOLUTIONS COR – 22.9 % (15875000 shares, share class: NO0012753625)
3. PHARMAMENTOR AS – 8.78 % (6085050 shares, share class: NO0012753625)
4. SIRO CLINPHARM PRIVATE LIMITED – 3.65 % (2528850 shares, share class: NO0012753625)
5. SCANPIPE ENGINEERING AS – 3.17 % (2200000 shares, share class: NO0012753625)
6. SILVERCOIN INDUSTRIES AS – 2.89 % (2000000 shares, share class: NO0012753625)
7. SKADI AS – 2.84 % (1966650 shares, share class: NO0012753625)
8. 3T HOLDING AS – 2.05 % (1421200 shares, share class: NO0012753625)
9. SMERUD MEDICAL RESEARCH INTERNATIONAL AS – 1.76 % (1219512 shares, share class: NO0012753625)
10. CHRISTIAN HENRIK THEISTE – 1.45 % (1003666 shares, share class: NO0012753625)
11. KONSTRUKT HOLDING AS – 1.13 % (780000 shares, share class: NO0012753625)
12. CAMACA AS – 1.03 % (716650 shares, share class: NO0012753625)
13. LETRON AS – 1.03 % (716650 shares, share class: NO0012753625)
14. MOMENT HOLDING AS – 0.88 % (609700 shares, share class: NO0012753625)
15. TROND DAHL-PEDERSEN – 0.87 % (600350 shares, share class: NO0012753625)
16. MARIA PATRICIA CONDE – 0.75 % (520000 shares, share class: NO0012753625)
17. ANDREAS NÆRDAL – 0.72 % (500000 shares, share class: NO0012753625)
18. VELU HOLDING AS – 0.63 % (435000 shares, share class: NO0012753625)
19. TANNLEGENE BENTE OG VEGARD BERG AS – 0.57 % (398300 shares, share class: NO0012753625)
20. MOHAMED ALAMOODI – 0.53 % (368672 shares, share class: NO0012753625)
21. PE CONSULT & HOLDING AS – 0.37 % (253300 shares, share class: NO0012753625)
22. TORFO AS – 0.36 % (250000 shares, share class: NO0012753625)
23. TORSEN TANKERS & TOWERS AS – 0.36 % (250000 shares, share class: NO0012753625)
24. UBS SWITZERLAND AG – 0.35 % (243245 shares, share class: NO0012753625)
25. KN PROSJEKT AS – 0.35 % (242500 shares, share class: NO0012753625)
26. RUNHILD GAMMELSÆTER – 0.32 % (220453 shares, share class: NO0012753625)
27. HANS MAGNUS WINTERMAN – 0.32 % (220000 shares, share class: NO0012753625)
28. TUCUME GROUP CORPORATION – 0.31 % (217050 shares, share class: NO0012753625)
29. MEDI PARTNER HOLDING AS – 0.29 % (200000 shares, share class: NO0012753625)
30. LARS DALBØGE HELDRE – 0.26 % (183333 shares, share class: NO0012753625)
31. ERLING REIN – 0.25 % (170000 shares, share class: NO0012753625)
32. PER HEIBERG DYBWAD – 0.24 % (169182 shares, share class: NO0012753625)
33. MALO INVEST AS – 0.24 % (166650 shares, share class: NO0012753625)
34. SIRIUSUNGEN AS – 0.24 % (166650 shares, share class: NO0012753625)
35. ANDERS SENUMSTAD HAUGE – 0.24 % (165000 shares, share class: NO0012753625)
36. OSKAR INVESTMENT AS – 0.22 % (150000 shares, share class: NO0012753625)
37. SAPAN MUNUSWAMY – 0.21 % (144700 shares, share class: NO0012753625)
38. SALVE TØNNESLAND – 0.19 % (135000 shares, share class: NO0012753625)
39. SOGN INVEST AS – 0.19 % (133350 shares, share class: NO0012753625)
40. TORJUSSEN CONSULTING AS – 0.19 % (133300 shares, share class: NO0012753625)
41. KIM REIDAR ANGERMAN – 0.19 % (133000 shares, share class: NO0012753625)
42. PETTER PENTTI DRAGVOLD – 0.19 % (128700 shares, share class: NO0012753625)
43. THOMAS FALCH ROSTAD – 0.18 % (121950 shares, share class: NO0012753625)
44. SANNE INVESTMENTS AS – 0.17 % (120000 shares, share class: NO0012753625)
45. CECILIE DAHLE-NEDRELID – 0.14 % (100000 shares, share class: NO0012753625)
46. GAUS CONSULT AS – 0.14 % (100000 shares, share class: NO0012753625)
47. JOHNNY HALS – 0.14 % (100000 shares, share class: NO0012753625)
48. KIRSTI SØRBØ – 0.14 % (100000 shares, share class: NO0012753625)
49. TOMMY LARSEN – 0.14 % (100000 shares, share class: NO0012753625)
50. FUNKSPORT AS – 0.14 % (99997 shares, share class: NO0012753625)

Fetch a longer owner list

Company holdings

No holdings found.

Grants and support

Sources provided through Firmafakta: Innovation Norway, the EU, the Research Council of Norway and SkatteFUNN.

Innovasjon Norge (1)

1 results

1. fylkesnavn:

   Agder

   kommunenavn:

   Arendal

   org_nr:

   925128554

   bedriftsnavn:

   INSULIFE AS

   virkemiddelkategori:

   Oppstartstilskudd

   underkategori:

   Landsdekkende etablerertilskudd

   innvilget_belop:

   750000

   innvilget_dato:

   22.06.20

   beslutningsenhet:

   IN Agder

   naringshovedgruppe:

   C - Industri

   naring:

   21.200 Produksjon av farmasøytiske preparater

   type_finansiering:

   Tilskudd

EU-tildelinger (0)

No registered grants.

Forskningsrådet (2)

2 results

1. id:

   77301

   prosjektnummer:

   346812

   prosjekttittel:

   Clinical development - Transdermal delivery of Insulin

   prosjektstart:

   2024

   prosjektslutt:

   2025

   prosjektansvarlig_navn:

   INSULIFE AS

   organisasjonsnummer:

   925128554

   sokt_belop:

   Endokrinologi

   tildelt_belop:

   0.0

   virkemiddel:

   Felleskostnader

   aktivitet:

   Utlysningsaktiviteter

2. id:

   74076

   prosjektnummer:

   340899

   prosjekttittel:

   Transdermal delivery of insulin by way of spraying on the skin: clinical phase 1 and 2a studies.

   prosjektstart:

   2023

   prosjektslutt:

   2024

   prosjektansvarlig_navn:

   INSULIFE AS

   organisasjonsnummer:

   925128554

   sokt_belop:

   Endokrinologi

   tildelt_belop:

   0.0

   virkemiddel:

   Felleskostnader

   aktivitet:

   Utlysningsaktiviteter

SkatteFUNN (2)

2 results

1. id:

   68919

   innsendt_dato:

   2023-08-31

   prosjektnummer:

   348645

   bedriftsnavn:

   INSULIFE AS

   prosjekttittel:

   Transdermal delivery of Insulin

   organisasjonsnummer:

   925128554

   fylke:

   Oslo

   kommunenavn:

   Oslo

   poststed:

   OSLO

   soknad_godkjent:

   JA

   soknad_avslatt:

   NEI

   vedtaksdato:

   2023-11-29

   prosjekt_fra_ar:

   2023

   prosjekt_til_ar:

   2025

   sammendrag:

   The pre-clinical and clinical testing of transdermal delivery of insulin

2. id:

   59822

   innsendt_dato:

   2020-08-31

   prosjektnummer:

   319131

   bedriftsnavn:

   INSULIFE AS

   prosjekttittel:

   Clinical development of Insulin Spray

   organisasjonsnummer:

   925128554

   fylke:

   Agder

   kommunenavn:

   Arendal

   poststed:

   ARENDAL

   soknad_godkjent:

   JA

   soknad_avslatt:

   NEI

   vedtaksdato:

   2020-10-15

   prosjekt_fra_ar:

   2020

   prosjekt_til_ar:

   2022

   sammendrag:

   Insulife AS is a Norwegian company with an exclusive licence to commercialize Levellor, a spray-on insulin being absorbed through the skin. The license implies that Insulife is responsible for clinical documentation needed to be granted Marketing Authorization from the European Medicines Agency. Levellor is developed by HSP Pharma in the US. As Insulin is a well known molecule which have been used to treat diabetes for more than 100 years, safety and efficacy of the active ingredient is well documented. What needs to be documented, is that Levellor sprayed on the skin gives the same biological effect on blood sugar as injected insulin. Insulife will intiate a formal Scientific Advice procedure with the European Medicines Agency (EMA) to secure that the studies we perform are aligned with the view from EMA. We will source Levellor for clinical studes from HSP in the US and perform the studies in cooperation with Smerud Medical Research International and the National Hospital (Rikshospitalet). Type 2-diabetes patients will be recruited for the clinical studies. This is based on less safety concern and a higher number of patients that can benefit from Levellor. Results from the clinical studies will be published in peer-reviewed medical journals. The end goal of the project is to file a an application for marketing authorization with the European Medicines Agency. This Marketing Authorization is a pre-requisite for commercializing Levellor in Europe.

Subunits

• INSULIFE AS (925196452)

Open positions

count:

0

stillinger:

No results.

Related lookups

• Doffin notices where INSULIFE AS is the buyer
• Search broadly for INSULIFE AS in Doffin
• Open positions related to INSULIFE AS
• Latest financial statement
• Patents and trademarks
• Official entity information from the Brønnøysund Register Centre
• Official roles from the Brønnøysund Register Centre
• Corporate group structure from the Brønnøysund Register Centre